Clinical Effectiveness of TARA Compared to Standard Treatment for Adolescents and Young Adults With Depression

Depressive Disorder Clinical Trial

— TARA  

Official title:

Clinical Effectiveness of Training for Awareness Resilience and Action (TARA) Compared to Standard Treatment for Adolescents and Young Adults With Depression, a Pragmatic Multi-center Randomised Controlled Superiority-trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04747340
• Other study ID #: TARA
• Status: Recruiting
• Phase: N/A
• Start date: March 12, 2021
• Est. completion date: January 1, 2029

Study information

• Verified date: April 2024
• Source: Umeå University
• Contact: Eva Henje, MD, PhD
• Phone: +46 738019212
• Email: eva.henje[@]umu.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Depressive Disorders constitute an increasing global health concern and available treatments for young people have not been sufficiently effective in haltering this trend. The novel group treatment program "Training for Awareness, Resilience, and Action" (TARA) was developed to target specific mechanisms based on neuroscientific findings in adolescent depression. TARA is framed within the National Institute of Mental Health's Research Domain Criteria and has documented feasibility and preliminary efficacy in adolescents with depression.

In this study, young people (age: 15-22) with depression will be recruited from specialized Child and Adolescent Psychiatry and Youth Clinics and randomized to receive either TARA or Standard Treatment (ST) until n=67 is reached in each arm. Outcome measures will be obtained before randomization (T0), 6 weeks after treatment start (T0.5), at 3- and 6 months follow-up (T1, T2). The primary outcome measure is Reynold's Adolescent Depression Scale (RADS-2) score at T1. Secondary outcome measures are RADS-2-score at T2, clinician depression rating with Children's Depression Rating Scale, Revised at T1,and self-rated anxiety with Multidimensional Anxiety Scale for Children, 2nd ed. at T1 and T2.

Other outcomes include heart rate variability and systemic bioindicators for depression from blood and hair. Data collected from subgroups within the study will include: brain magnetic resonance imaging and accelerometry. Qualitative interviews will be performed to reach a more comprehensive understanding of the subjective experience of being depressed and to what extent treatment adequately addresses this experience. A 2-year follow-up (T3) will be performed and presented separately.

The study will be the first Randomized Controlled Trial to examine the clinical effectiveness of TARA compared to ST for young people with depression. The investigators hypothesize that (1) TARA will result in greater reduction of depression symptoms compared to ST and that group differences will be maintained or increased at T2, (2) the treatment effect of TARA will be mediated by improved emotion regulation, sleep, and psychological flexibility, (3) bioindicators for depression will improve more in the TARA-arm compared to the ST-arm, (4) it will be possible/meaningful to explore the contextual factors perceived to drive the depression onset and maintenance, and the extent to which the different treatments address these factors.

Description:

The primary aim of this study is to investigate the clinical effectiveness of TARA in treating depression in adolescents and young adults by using a Randomized Controlled Trial (RCT)-design, with an active control group based on standard treatment (ST) for depression in Child and Adolescent Psychiatry (CAP) and Youth Clinics (YC). Secondary aims are: 1. to identify potential mediating effects of improved emotion regulation, sleep and psychological flexibility on the treatment effect of TARA, 2. Investigate the effects the two treatment-arms on bioindicators for depression, 3. Increase the understanding of the subjective experience of depression onset and to what extent the treatments addressed what is perceived to drive the onset and maintenance of depression.

The study is designed as a partially nested multicenter parallel-group RCT with two treatment arms: 1) TARA and 2) ST, including but not limited to anti-depressive medication such as selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy. Participants are randomized to one of the two treatment arms, both delivered via the local CAP and YC unit where the participants are being either referred to, are wait-listed or treated. The study is planned in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and will be analyzed and reported in accordance with the recommendations in consolidated standards of reporting trials (CONSORT).

Participants and procedures

Recruitment, treatment and data collection will be conducted in three cities in Northern Sweden, each with 1-2 centers. Several centers will be included step-wise in the RCT, until a sufficient recruitment capacity has been reached. Before including a new center the implementation of Good Clinical Practice-guide-lines, a clinical research infrastructure and the training of study-staff must be satisfactory and a pilot trial will have been conducted at each site to show feasibility. The investigators intend to recruit participants from the Child- and adolescent psychiatry (CAP) specialized outpatient academic unit and the youth outpatient community clinic (YC) in the university city Umeå (population 89 000), CAP and YC in Skellefteå (population 36 000) and CAP in Örnsköldsvik (population 33 000). The CAP unit in Sundsvall (population 55 000) is also prepared for participation, this center will be activated only if needed to maintain recruitment pace. Depending on the general recruitment rate and the feasibility of implementation of the study protocol at the different sites, one or several of the sites may be omitted.

Adolescents and young adults (15-22 years of age) with depression will be recruited to the RCT. In this study depression is defined as having a diagnosis of major depressive disorder (MDD) or persistent depressive disorder (PDD) according to DSM 5 (dysthymia in DSM-IV) or a clinician depression rating >40 using Children's Depression Rating Scale - Revised (CDRS-R). The recruitment is done through three possible pathways: 1) at the time of an incoming referral, 2) by clinical staff who recruit potential participants at their first clinical visit, from those wait-listed for treatment, or during ongoing standard treatment and 3) by participants responding to flyers posted in the local waiting-rooms and at the student health clinic at the University of Umeå.

Those who show interest in participating in the study after having received introductory information, will be provided more detailed information over the phone. At that time initial assessment for eligibility will also be performed. Further eligibility-screening is then performed online and in person (see inclusion and exclusion criteria). The decision to include a participant in the study will be made by a study-clinician on the basis of the eligibility criteria and the final decision in case of uncertainty will be made by the PI.

Before final inclusion, participants will provide written informed consent. In addition, parents/legal guardians will provide written informed consent for participants that are <18 years old. Study participation is voluntary and can be cancelled by the participant at any time.

Participants randomized to TARA who are taking antidepressant medication with maintained depressive symptoms will be offered support from a child psychiatrist to discontinue their medication over a period of 2-4 weeks and start TARA as a stand-alone treatment. Those who prefer to continue their antidepressant medication and those who require more extensive tapering regimens will still be included in the study, enter treatment as allocated and be analyzed according to the intention to treat design.

All ST will take place at the local CAP and YC units and/or be delivered online. Any worsening of symptoms during the ST will be handled by the clinic according to their standard procedures. TARA will be delivered as an online group-intervention and routines for handling potential increase of depression symptoms during TARA are explained in detail in the study protocol.

Assessment procedure

At baseline, before inclusion, self-report of sociodemographic background, social support, dissociative symptoms and adverse childhood events is completed.

After inclusion and before randomization (T0), at 3 months (T1), at 6 months (T2) and at 2 years (T3) from T0 additional self-report questionnaires are completed, for details see outcome measures. Clinician rating of depression symptom severity and global level of functioning is conducted at T0 and T1. Blood and hair samples are collected and heart rate variability (HRV) is measured at T0 and T1.

For a subgroup of randomly selected participants from both study arms in the Umeå YC/CAP-populations a 2-3 weeks of accelerometry will also be carried out at T0, 6 weeks into the study (T0,5) and at T1. MRI data acquisition will be performed at T0 and T1 in approximately n=22 randomly selected participants from each study arm from the Umeå YC/CAP-populations. MRI data acquisition will not start at the beginning of the study but will be initiated at a later time.

The TARA-participants will provide brief self-assessment and session-evaluation at the beginning and end of each session. Additionally, to evaluate mediation effects of emotion regulation, sleep and psychological flexibility three self-report scales will be administered halfway through the TARA-treatment.

Participants who do not show up for data collection will be reminded by the research team through email and/or telephone contact.

Randomization

When 6 eligible participants have been recruited at a study-site, these participants will all undergo T0 assessments within a period of 2 weeks. Next, the participants will be randomized as a group to one of the two study arms in a 1:1 allocation ratio, by a computer-generated allocation sequence using permuted blocks and stratification for center. Block sizes will vary randomly between 2 and 4 and the first value on the randomization list at each center will be discarded at random with 50% probability to reduce the risk of breaking the allocation concealment. Randomization will continue until n=67 has been reached in each arm. Codes will be used to increase information confidentiality and participant anonymity. Treatment allocation will be performed on the basis of these codes, by a different team at the Umeå University clinical research center (CRC). The CRC will not release the randomization results until the participants have been recruited into the trial and all baseline and T0 assessments have been completed. The process will thus be separate from the patient enrolment process at the clinics. Participants, TARA-facilitators and standard treatment personnel cannot be blind to treatment allocation, but clinical outcome-assessors and statistical analysts will be blinded.

Analysis

Data from the pilot-groups at each site will be analyzed and presented separately.

For the RCT, the analyses will be performed after the last participant is out and data collection at T2 is complete. No interim analyses will be conducted. Descriptive statistics will be reported using standard measures and the baseline characteristics of the included participants will be reported per randomization group in a baseline table.

All randomized participants will be included in the main analysis that will be performed according to intention to treat. The primary outcome RADS-2 total raw-score at 3 months follow up (T1) aims to investigate the differences between the two treatment arms in reduction of depressive symptoms and will be analyzed using mixed effects modelling to account for the clustering caused by partial nesting. The main mixed effects model will include fixed effects for treatment allocation, RADS-2-score at T0, age-group (dichotomous, 15-17 and 18-22 years old), study site and sex. The clustering effect will be modelled using a random intercept for each intervention group.

Superiority will be concluded if 95% confidence intervals are not overlapping between the two study-arms. Additionally, a non-inferiority margin is defined as a RADS-2 total raw-score difference of 8 points. The investigators consider this to be the maximal clinically acceptable difference in light of the other potential benefits of TARA. If superiority is not demonstrated, additional specific equivalence- and non-inferiority analyses will be performed. Since participants who withdraw or drop out may tend to have a lack of response, using the full analysis set is likely to be biased toward demonstrating non-inferiority. Therefore, a per-protocol population (defined in the study protocol) will be used in this analysis. Additionally, to avoid making biased conclusions based on the per-protocol population the analysis will also be performed on the intention to treat population and non-inferiority will be concluded if the analyses reach similar results.

Participants who do not show up for T0 assessment will not be randomized and will be considered external dropouts. Participants who complete T0-assessment and drop out before randomization will also be considered external dropouts. Participants who are randomized but do not show up for treatment or show up but do not complete the allocated treatment will be considered internal dropouts and will be included in the analysis. All participants lost to follow-up will be contacted and asked about the reason for the drop-out. This will enable a comparison between the study arms regarding the reasons for drop-out and an examination of potential sources of bias in attrition.

Additional sensitivity analyses will be performed on the primary outcome to test the robustness of findings.

Secondary outcome variables will be analyzed by using similar mixed effects models as for the primary outcome, and adjusting for the T0-value for each respective outcome. Time-point (T0, T1, T2) and the allocation by time interaction will be included as fixed effects in these models.

Time plan

Recruitment for the RCT has started. The final data collection at T2 is estimated to be completed in 2025.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 134
• Est. completion date: January 1, 2029
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years to 22 Years

Eligibility

Inclusion Criteria:

• Outpatient at the CAP or YC unit

• The criteria for a diagnosis Major Depressive Disorder (MDD) or Persistent Depressive disorder (PDD)/dysthymia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV or 5 are fulfilled. The clinical diagnosis will be validated during the screening process using the Mini International Neuropsychiatric Interview (M.I.N.I.)/Mini-International Neuropsychiatric Interview for Children and Adolescents (M.I.N.I-kid). If a diagnosis of MDD or PDD/dysthymia is not conclusive a cut-off of 40 or above on the Children's' Depression Rating Scale - Revised will be used for inclusion.

• For patients in specialist child- and adolescent psychiatry clinics below the age of 18 one parent/ legal guardian must be available and agree to participate in parts of the sessions in case the individual is randomized to the TARA-arm.

Exclusion Criteria:

1. One or several severe psychiatric co-morbid diagnoses that may interfere with or hinder group participation, including: intellectual development disorder, severe autism spectrum disorder, psychotic disorder, bipolar disorder, severe anorexia nervosa, substance use disorders, acute posttraumatic stress disorder (PTSD) and severe dissociative syndromes.

2. One or several psychiatric symptoms or behavioral problems that may interfere with or hinder group participation including:

• Severe self-harming behavior

• Acute suicidality, including a reported suicide attempt in the last 6 months or hospitalization for suicidality in the last 6 months

• Disabling dissociative symptoms or > 6 points as mean item score on the Adolescent Dissociative Experiencing Scale.

• Frequent use of recreational drugs (a urine drug screen will be performed at baseline and if positive a second test has to be negative for inclusion)

• Reports of manic or hypomanic symptoms during the last year

3. A first degree relative with bipolar disorder (a first episode of MDD may be an incipient bipolar disorder which is not the treatment target for TARA).

4. On-going trauma, neglect, abuse or domestic violence or destabilizing legal process.

5. Pregnancy

6. Non-fluency in oral and written Swedish since the TARA groups are held in Swedish and assessment forms are in Swedish

Note:

Other psychiatric comorbidities such as attention deficit hyperactivity disorder (ADHD), anxiety, high functioning autism spectrum disorder and mild to moderate eating disorders are not considered exclusion criteria.

Accidental findings of biochemical anomalies will not be considered exclusion criteria and medical conditions will be referred for appropriate treatment.

Related Conditions & MeSH terms

• Depression
• Depression in Adolescence
• Depressive Disorder
• Dysthymia and Chronic Depression
• Dysthymic Disorder

Intervention

Behavioral:
• Training for Awareness Resilience and Action (TARA)
See arm-description

Other:
• Standard treatment
See arm-description

Locations

Country	Name	City	State
Sweden	Barn och Ungdomspsykiatriska kliniken	Örnsköldsvik And Sundsvall	Västernorrland
Sweden	Ungdomshälsan/primary care	Umeå And Skellefteå	Västerbotten
Sweden	Barn och Ungdomspsykiatriska kliniken	Umeå, Skellefteå, And Lycksele	Västerbotten

Sponsors (3)

Lead Sponsor	Collaborator
Umeå University	Västerbotten County Council, Sweden, Västernorrland County Council, Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Reynold's Adolescent Depression Scale 2nd edition	Self-report. Total raw-score. Raw scores range is 30-120 and higher scores mean a worse outcome.	2-year follow-up
Other	Multidimensional Anxiety Scale for Children	Self-report. Raw score range is 0-117 and higher scores indicate a worse outcome.	2-year follow-up
Other	Insomnia Severity Index	Self-report. Raw score range is 0-28 and higher scores indicate a worse outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Perceived Stress Scale	Self-report. Raw score range is 0-40 and higher scores indicate a worse outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Avoidance and Fusion Questionnaire for Youth	Self-report. Raw score range is 0-32 and higher scores indicate a worse outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Difficulties in Emotion Regulation Skills	Self-report. Raw score range is 16-80 and higher scores indicate a worse outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Compassionate Engagement and Action Scales - youth	Self-report. Raw score range is 0-270 and higher scores indicate a better outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Strengths and Difficulties Questionnaire	Self-report. Raw score range is 0-40 and higher scores indicate a worse outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	EuroQualityOfLife - 5 Dimensions - Youth	Self-report. Raw score range is 5-15 and higher scores indicate a worse outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Deliberate Self Harm Inventory	Self-report. Raw score range is 0-54 and higher scores indicate a worse outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Montgomery Åsberg Depression Rating Scale - Youth	Self-report. Raw score range is 0-54 and higher scores indicate a worse outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Suicidal Ideation Questionnaire	Self-report. Raw score range is 0-90 and higher scores indicate a worse outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Emotional Breakthrough Inventory	Self-report. Raw score range is 0-100 and higher scores indicate a better outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Patient-Reported Outcomes Measurement System (PROMIS), anger subscale	Self-report. Raw score range is 0-36 and higher scores indicate a worse outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Patient-Reported Outcomes Measurement System (PROMIS), physical activity subscale	Self-report. Raw score range is 0-40 and higher scores indicate a better outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Multiscale Dissociative Inventory	Self-report. Raw score range is 30-150 and higher scores indicate a worse outcome.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Negative experiences questionnaire	Self-report.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Paediatric side effect checklist	Self-report.	3 month follow-up, 6 month follow-up and 2-year follow-up
Other	Heart rate variability	Bipolar Electrocardiography with no intervention after 15 min rest	3 month follow-up
Other	Sleep registration	3-axial accelerometry-derived sleep efficiency/fragmentation/latency	6 week follow-up and 3 month follow-up.
Other	Cortisol in hair	Average cortisol concentration in hair	3 month follow-up
Other	Neuro-inflammation assay	Mesoscale micro-array on blood plasma	3 month follow-up
Other	Growth factor assay	Mesoscale micro-array on blood plasma	3 month follow-up
Other	Telomere length	Telomere length measured in peripheral blood mononuclear cells	3 month follow-up
Other	Blood lipids	Standard lipid measures in blood plasma	3 month follow-up
Other	Endocrine markers	Standard endocrine measures in blood serum	3 month follow-up
Other	Avoidance and Fusion Questionnaire for Youth, mediation measure.	Self-rating. Mediation measure (TARA-arm participants only). Avoidance and Fusion Questionnaire for Youth. Raw score range is 0-32 and higher scores indicate a worse outcome.	6 week follow-up
Other	Insomnia Severity Index, mediation measure.	Self-rating. Mediation measure (TARA-arm participants only). Insomnia Severity Index. Raw score range is 0-28 and higher scores indicate a worse outcome.	6 week follow-up
Other	Difficulties in Emotion Regulation Skills, mediation measure	Self-rating. Mediation measure (TARA-arm participants only). Difficulties in Emotion Regulation Skills. Raw score range is 16-80 and higher scores indicate a worse outcome.	6 week follow-up
Primary	Reynold's Adolescent Depression Scale 2nd edition	Self report. Total raw-score. Raw score range is 30-120 and higher scores mean a worse outcome.	3 month follow-up
Secondary	Reynold's Adolescent Depression Scale 2nd edition	Self report. Total raw-score. Raw score range is 30-120 and higher scores mean a worse outcome.	6 month follow-up
Secondary	Children's Depression Rating Scale - Revised	Clinician rating. Raw score range is 17-113 and higher scores mean a worse outcome.	3 month follow-up
Secondary	Multidimensional Anxiety Scale for Children	Self-report. Raw score range is 0-117 and higher scores indicate a worse outcome.	3 month follow-up and 6 month follow-up